Segment polarity protein dishevelled homolog (DVL) (DVL)

Segment polarity protein dishevelled homolog (DVL) is a family of highly conserved scaffold proteins, comprising DVL1, DVL2, and DVL3 in humans, that act as a central hub in the Wnt signaling network [1, 4]. It functions by relaying signals from activated Frizzled receptors at the plasma membrane to various intracellular effectors, effectively branching the signal into canonical (beta-catenin dependent) and non-canonical (beta-catenin independent) pathways [2, 11]. Structurally, DVL is characterized by three conserved domains—DIX, PDZ, and DEP—which facilitate its recruitment to the membrane and its interaction with a wide array of binding partners [3, 14]. In many human malignancies, including colorectal, lung, and breast cancers, DVL is frequently overexpressed or aberrantly activated, leading to the stabilization of beta-catenin and the promotion of uncontrolled cell proliferation and metastasis [7, 15, 18]. Consequently, DVL has emerged as a promising therapeutic target, with drug development efforts focusing on small-molecule inhibitors, such as Sulindac and FJ9, designed to block its PDZ domain and disrupt oncogenic Wnt signaling [5, 7, 16]. However, therapeutic strategies must carefully manage the risk of inhibiting essential Wnt-mediated processes in normal stem cell niches and healthy tissues [1, 11].

Other names

DishevelledDshDVL1DVL2DVL3DSH homologSegment polarity protein dishevelled homolog 1Segment polarity protein dishevelled homolog 2Segment polarity protein dishevelled homolog 3

Small molecule inhibition of the PDZ domain to disrupt the protein-protein interaction between Dishevelled and Frizzled receptors, thereby down-regulating canonical Wnt/beta-catenin signaling and suppressing the expression of Wnt-target genes [5, 7, 16].